Harpoon Therapeutics, Inc.

Stock Symbol: 
Case Status: 

Ademi LLP is investigating Harpoon (Nasdaq: HARP)  for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

In the transaction, Harpoon stockholders will receive only $23.00 per share in cash for an approximate total equity value of $680 million. The transaction agreement unreasonably limits competing transactions for Harpoon by imposing a significant penalty if Harpoon accepts a competing bid. Harpoon insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Harpoon’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.